Skip to content

Effect of Empagliflozin in obsessive-compulsive disorder

Investigating the effect of adjunctive treatment of Empagliflozin in improving the symptoms of patients with moderate to severe obsessive-compulsive disorder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240529061948N1
Enrollment
54
Registered
2025-06-02
Start date
2025-06-27
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: 27 patients will receive empagliflozin 25 mg once daily in combination with fluvoxamine, starting at 100 mg once daily for one month, then increased to 200 mg dail

Sponsors

Karaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: People aged 18 to 60 who has DSM-5 diagnostic criteria for moderate to severe OCD. Consent of patients to participate in the study They have the Yale-Brown Algebraic Obsession Scale (Y-BOCS) above 21.

Exclusion criteria

Exclusion criteria: Being psychotic Have other disorders diagnosed in psychiatric axis I. Used any type of psychoactive drug in the last 6 weeks Have taken OCD medication in the last 6 weeks and ECT in the last two months Participation in psychotherapy sessions in the last 6 weeks Hypothyroidism History of cardiovascular disease Pregnancy or breastfeeding kidney disease Type 1 diabetes Age less than 18 and more than 60 IQ less than 70 History of seizures and brain disorders Taking beta-blocker drugs, amlodipine, insulin, glipizide, metformin, linagliptin, sitagliptin, liraglutide, lasix, lithium, linezolid Abuse of drugs and medicine except nicotine and caffeine Any type of kidney, urinary tract and genital infection The presence of MAO inhibitors such as Azilact, Marplan ?Aspirin, Gabapentin, Pantoprazole, and Omeprazole in the patient's medication list Pancreatitis Hypotension

Design outcomes

Primary

MeasureTime frame
OCD score according to the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Timepoint: 1st visit (before the intervention) and 4, 10, and 12 weeks after drug/placebo administration. Method of measurement: Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

Secondary

MeasureTime frame
Y-BOCS score. Timepoint: 1st day 4th week ,10th week and 12 week after administration of Empagliflozin /Placebo. Method of measurement: Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReyhaneh Hadi

Karaj University of Medical Sciences

reihanehhadi45@gmail.com+98 26 3419 3000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026